Headlines

Pfizer’s HYMPAVZI for Hemophilia A or B receives EU approval

The European Commission has approved Pfizer’s treatment for adults and adolescents with severe hemophilia A or B.

Samsung Biologics and European pharma company enter major manufacturing deal

The global CDMO has entered into several high-value manufacturing deals this year.

Paid for and in partnership with Lonza Small Molecules

Streamlining early phase drug development with continuous flow technologies

Lonza’s innovative continuous flow technology and mini-monoplant approach are transforming early-phase drug development. How can they accelerate timelines and reduce costs?

Tran Pham: Breaking barriers and building biopharma solutions

From discovering her knack for chemistry in high school to proving her expertise in male-dominated spaces, Tran Pham has built a dynamic career in biopharma.

C Ray Therapeutics raises $100 million to develop radiopharmaceuticals

The financing round will fund the improvement of the company’s technology platform for the discovery and development of innovative radionuclide drug conjugates.

Eli Lilly announces positive Phase 2 results for Muvalaplin against heart disease

Muvalaplin significantly lowered lipoprotein(a) levels, reducing the risk of cardiovascular events in high-risk adults.

Tirzepatide prevents type 2 diabetes in 99% of prediabetic patients for 3 years

Results from the SURMOUNT-1 trial show that weekly injections of tirzepatide could stop the progression from pre-diabetes to type 2 diabetes in 99% of participants.

Genesis Therapeutics partners with NVIDIA to boost AI-driven drug discovery

Genesis also announced a further investment from NVentures, NVIDIA’s venture capital arm.

AstraZeneca doubles down on US manufacturing with $3.5 billion investment

AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it unveils a $3.5 billion infusion into US sites.